NASDAQ:INGN - Inogen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $73.50
  • Forecasted Upside: 15.75 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$63.50
▼ -0.97 (-1.50%)
1 month | 3 months | 12 months
Get New Inogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$73.50
▲ +15.75% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Inogen in the last 3 months. The average price target is $73.50, with a high forecast of $75.00 and a low forecast of $72.00. The average price target represents a 15.75% upside from the last price of $63.50.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in Inogen. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
i
Rating by M. Kaczor at William Blair
5/5/2021SVB LeerinkBoost Price TargetMarket Perform$67.00 ➝ $72.00High
i
5/5/2021KeyCorpBoost Price TargetPositive ➝ Overweight$60.00 ➝ $75.00High
i
2/25/2021SVB LeerinkBoost Price TargetMarket Perform$47.00 ➝ $54.00High
i
12/14/2020KeyCorpUpgradeSector Weight ➝ Overweight$60.00High
i
11/13/2020Needham & Company LLCReiterated RatingHoldMedium
i
8/5/2020SVB LeerinkLower Price TargetMarket Perform$42.00 ➝ $35.00High
i
7/23/2020Needham & Company LLCDowngradeBuy ➝ HoldHigh
i
6/10/2020William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Kaczor at William Blair
6/1/2020SVB LeerinkBoost Price TargetMarket Perform$42.00 ➝ $56.00Medium
i
5/6/2020SVB LeerinkLower Price TargetMarket Perform$68.00 ➝ $56.00High
i
5/6/2020Needham & Company LLCLower Price TargetBuy$80.00 ➝ $75.00High
i
Rating by Michael Matson at Needham & Company LLC
2/26/2020JPMorgan Chase & Co.Lower Price TargetUnderweight$60.00 ➝ $45.00High
i
12/20/2019JPMorgan Chase & Co.Boost Price TargetUnderweight$47.50 ➝ $60.00Low
i
Rating by Robert Marcus at JPMorgan Chase & Co.
11/22/2019Needham & Company LLCReiterated RatingBuy$90.00Low
i
Rating by Michael Matson at Needham & Company LLC
11/6/2019Needham & Company LLCUpgradeHold ➝ Buy$90.00Medium
i
Rating by Michael Matson at Needham & Company LLC
8/8/2019SVB LeerinkReiterated RatingOutperform ➝ Market Perform$78.00 ➝ $47.00High
i
Rating by D. Antalffy at SVB Leerink LLC
8/7/2019KeyCorpReiterated RatingHoldMedium
i
Rating by Matthew Mishan at KeyCorp
8/7/2019Piper Jaffray CompaniesLower Price TargetOverweight$140.00 ➝ $80.00High
i
8/7/2019Stifel NicolausDowngradeBuy ➝ Hold$85.00 ➝ $48.00High
i
8/7/2019Needham & Company LLCDowngradeBuy ➝ HoldLow
i
7/3/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$72.00Low
i
6/28/2019Needham & Company LLCDowngradeStrong-Buy ➝ Buy$111.00 ➝ $91.00High
i
5/8/2019Stifel NicolausLower Price TargetBuy$160.00 ➝ $85.00High
i
5/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$175.00 ➝ $72.00High
i
5/8/2019Needham & Company LLCLower Price TargetStrong-Buy ➝ Strong-Buy$191.00 ➝ $111.00Medium
i
4/9/2019Needham & Company LLCReiterated RatingBuy$191.00Low
i
2/27/2019JPMorgan Chase & Co.Lower Price TargetPositive ➝ Overweight$175.00High
i
2/27/2019Piper Jaffray CompaniesLower Price TargetOverweight$290.00 ➝ $185.00High
i
2/27/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$280.00 ➝ $191.00High
i
11/26/2018Needham & Company LLCBoost Price TargetBuy ➝ Strong-Buy$280.00Low
i
11/20/2018Needham & Company LLCUpgradeBuy ➝ Strong-Buy$280.00 ➝ $280.00High
i
11/7/2018Needham & Company LLCReiterated RatingBuy$296.00 ➝ $280.00High
i
9/12/2018Piper Jaffray CompaniesBoost Price TargetOverweight$245.00 ➝ $290.00Medium
i
Rating by JP McKim at Piper Jaffray Companies
9/10/2018Needham & Company LLCDowngradeStrong-Buy ➝ Buy$254.00 ➝ $296.00Low
i
8/21/2018Stifel NicolausSet Price TargetBuy$258.00Medium
i
Rating by Mathew Blackman at Stifel Nicolaus
8/8/2018Needham & Company LLCBoost Price TargetStrong-Buy$215.00 ➝ $254.00High
i
8/7/2018Piper Jaffray CompaniesBoost Price TargetOverweight$245.00High
i
Rating by JP McKim at Piper Jaffray Companies
7/9/2018Piper Jaffray CompaniesBoost Price TargetOverweight$235.00High
i
Rating by JP McKim at Piper Jaffray Companies
6/13/2018Needham & Company LLCReiterated RatingBuyLow
i
6/6/2018KeyCorpInitiated CoverageEqual WeightLow
i
5/1/2018SVB LeerinkReiterated RatingOutperform$150.00 ➝ $170.00High
i
5/1/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$150.00 ➝ $180.00High
i
5/1/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$150.00 ➝ $215.00Low
i
4/30/2018Piper Jaffray CompaniesBoost Price TargetOverweight$190.00High
i
Rating by JP McKim at Piper Jaffray Companies
4/14/2018Piper Jaffray CompaniesSet Price TargetBuy$145.00Low
i
Rating by JP McKim at Piper Jaffray Companies
3/27/2018Needham & Company LLCReiterated RatingBuy$150.00High
i
2/28/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$125.00 ➝ $150.00High
i
2/20/2018Piper Jaffray CompaniesUpgradeNeutral ➝ OverweightMedium
i
11/8/2017SVB LeerinkReiterated RatingOutperform$115.00 ➝ $120.00N/A
i
11/8/2017Needham & Company LLCBoost Price TargetStrong-Buy$108.00 ➝ $125.00N/A
i
9/12/2017Piper Jaffray CompaniesReiterated RatingHold$90.00Low
i
9/1/2017Needham & Company LLCReiterated RatingBuy$108.00Medium
i
6/26/2017JPMorgan Chase & Co.Boost Price TargetOverweight$102.00Low
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
6/9/2017Needham & Company LLCBoost Price TargetStrong-Buy$96.00 ➝ $108.00Low
i
6/8/2017Needham & Company LLCLower Price TargetStrong-Buy$108.00 ➝ $96.00High
i
5/10/2017Stifel NicolausBoost Price TargetHold ➝ Hold$65.00 ➝ $75.00High
i
5/10/2017Needham & Company LLCReiterated RatingBuy$96.00High
i
4/18/2017SidotiInitiated CoverageNeutral ➝ Neutral$79.00Medium
i
4/5/2017Needham & Company LLCReiterated RatingBuy$83.00Medium
i
3/1/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/A
i
Rating by Robbie Marcus at JPMorgan Chase & Co.
3/1/2017Stifel NicolausBoost Price Target$65.00N/A
i
3/1/2017Needham & Company LLCBoost Price TargetStrong-Buy$78.00 ➝ $83.00N/A
i
1/19/2017Needham & Company LLCBoost Price TargetStrong-Buy$66.00 ➝ $78.00N/A
i
1/19/2017Needham & Company LLCInitiated CoverageStrong-BuyN/A
i
11/4/2016Needham & Company LLCBoost Price TargetStrong-Buy$64.00 ➝ $66.00N/A
i
Rating by Michael Matson at Needham & Company LLC
8/7/2016Needham & Company LLCReiterated RatingStrong-Buy$58.00 ➝ $64.00N/A
i
Rating by Michael Matson at Needham & Company LLC
8/5/2016JPMorgan Chase & Co.Boost Price TargetOverweight$60.00 ➝ $62.00N/A
i
8/5/2016Stifel NicolausDowngradeBuy ➝ HoldN/A
i
Rating by Thomas Carroll at Stifel Nicolaus
7/13/2016JPMorgan Chase & Co.Initiated CoverageOverweightN/A
i
(Data available from 6/14/2016 forward)
Inogen logo
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
Read More

Today's Range

Now: $63.50
$62.92
$64.53

50 Day Range

MA: $62.88
$52.03
$68.22

52 Week Range

Now: $63.50
$26.57
$69.00

Volume

103,988 shs

Average Volume

156,892 shs

Market Capitalization

$1.42 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Inogen?

The following equities research analysts have issued research reports on Inogen in the last twelve months: KeyCorp, Needham & Company LLC, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for INGN.

What is the current price target for Inogen?

2 Wall Street analysts have set twelve-month price targets for Inogen in the last year. Their average twelve-month price target is $73.50, suggesting a possible upside of 15.7%. KeyCorp has the highest price target set, predicting INGN will reach $75.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $72.00 for Inogen in the next year.
View the latest price targets for INGN.

What is the current consensus analyst rating for Inogen?

Inogen currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INGN will outperform the market and that investors should add to their positions of Inogen.
View the latest ratings for INGN.

What other companies compete with Inogen?

How do I contact Inogen's investor relations team?

Inogen's physical mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company's listed phone number is 805-562-0500 and its investor relations email address is [email protected] The official website for Inogen is www.inogen.com.